Trial reportJournal of investigative medicine : the official publication of the American Federation for Clinical Research2013
Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients.
Trial report in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.International urology and nephrology · 2023Trial
- Trial
- Therapeutic Potential of Myricitrin in aMolecules (Basel, Switzerland) · 2025Article
- Gut microbiota and obesity: New insights.Frontiers in nutrition · 2022Review
- Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism.JCI insight · 2021Article
- Remodeling adipose tissue inflammasome for type 2 diabetes mellitus treatment: Current perspective and translational strategies.Bioengineering & translational medicine · 2020Review
- Adipose Tissue Immunomodulation: A Novel Therapeutic Approach in Cardiovascular and Metabolic Diseases.Frontiers in cardiovascular medicine · 2020Review
- To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations.PPAR research · 2020Article
- Rosiglitazone remodels the lipid droplet and britens human visceral and subcutaneous adipocytes ex vivo.Journal of lipid research · 2019Article
- Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes.Frontiers in physiology · 2019Review
- Diabetes and Sepsis: Risk, Recurrence, and Ruination.Frontiers in endocrinology · 2017Review
- Deciphering the Roles of Thiazolidinediones and PPARPPAR research · 2017Review
- Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis.Clinical & translational immunology · 2016Review
- Obesity: An Immunometabolic Perspective.Frontiers in endocrinology · 2016Review
- Mechanisms by which the thiazolidinedione troglitazone protects against sucrose-induced hepatic fat accumulation and hyperinsulinaemia.British journal of pharmacology · 2016Article
- Hypoglycemic agents and potential anti-inflammatory activity.Journal of inflammation research · 2016Review
- Regulation of metabolism by the innate immune system.Nature reviews. Endocrinology · 2016Review
- Pioglitazone in adult rats reverses immediate postnatal overfeeding-induced metabolic, hormonal, and inflammatory alterations.Endocrine · 2015Article
- Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population.Current therapeutic research, clinical and experimental · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe American Diabetes Association has called for further research on how patients' demographics should determine drug choices for individuals with type 2 diabetes mellitus (T2DM). Here, using in-depth physiology studies, we investigate whether obese patients with T2DM are likely to benefit from thiazolidinediones, medications with a known adverse effect of weight gain. MATERIALS AND
methodsEleven obese and 7 nonobese individuals with T2DM participated in this randomized, placebo-controlled, double-blind, crossover study. Each subject underwent a pair of "stepped" pancreatic clamp studies with subcutaneous adipose tissue biopsies after 21 days of pioglitazone (45 mg) or placebo.
resultsObese subjects demonstrated significant decreases in insulin resistance and many adipose inflammatory parameters with pioglitazone relative to placebo. Specifically, significant improvements in glucose infusion rates, suppression of hepatic glucose production, and whole fat expression of certain inflammatory markers (IL-6, IL-1B, and inducible nitric oxide synthase) were observed in the obese subjects but not in the nonobese subjects. Additionally, adipose tissue from the obese subjects demonstrated reduced infiltration of macrophages, dendritic cells, and neutrophils as well as increased expression of factors associated with fat "browning" (peroxisome proliferator-activated receptor gamma coactivator-1α and uncoupling protein-1).
conclusionsThese findings support the efficacy of pioglitazone to improve insulin resistance and reduce adipose tissue inflammation in obese patients with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.